Expression, purification and characterization of recombinant targeting bifunctional hirudin in Pichia pastoris

African Journal of Biotechnology

Volumn 8, Issue 20, 2009, Pages 5571-5577

  Hu, Zongli ^a   Zhang, Ning ^a   Gu, Feng ^a   Li, Yong ^a   Deng, Xiaojie ^a   Chen, Guoping ^a  

^a CHONGQING UNIVERSITY   (China)

Author keywords

Anticoagulant; Bifunctional; Hirudin; Pichia pastoris; Recombinant; Targeting

Indexed keywords

ANTITHROMBIN; ARGINYLGLYCYLASPARTIC ACID; BLOOD CLOTTING FACTOR 10A; HYBRID PROTEIN; PLASMID VECTOR; POLYHISTIDINE TAG; RECOMBINANT TARGETING BIFUNCTIONAL HIRUDIN; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ARTERY THROMBOSIS; ARTICLE; BACTERIAL STRAIN; ESCHERICHIA COLI; EXPRESSION VECTOR; GENE LOCUS; MOLECULAR CLONING; NONHUMAN; PICHIA PASTORIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; THROMBOCYTE AGGREGATION;

PICHIA PASTORIS;

EID: 73349104093     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Bar-Shavit R, Eldor A, Vlodavsky I (1989). Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties. J. Clin. Invest. 84(4): 1096-1104.
2. Bennett JS (2001). Novel platelet inhibitors. Annu. Rev. Med. 52: 161-184.
3. Breddin HK (2002). Current developments in antithrombotic therapy: the role of antithrombin agents. Pathophysiol. Haemost. Thromb. 32(3): 1-8.
4. Dodt J, MÜller HP, SeemÜller U, Chang JY (1984). The complete amino acid sequence of hirudin, a thrombin specific inhibitor. FEBS lett. 165: 180-184.
5. Harker LA, Hanson SR, Kelly AB (1997). Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb. Haemost. 78(1): 736-741.
6. Imura Y, Stassen J M, Bunting S, Stockmans F, Collen D (1992). Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp- sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model. Blood, 80(5):1247-1253.
7. Mann KG (1994). The coagulation explosion. Ann. N. Y. Acad. Sci. 714: 265-269.
8. Markwardt F, Sturzebecker J, Griessbach U (1970). Hirudin as an inhibitor of thrombin naturally occurring activators and inhibitors. Meth. Enzymol. 19: 924-932.
9. Markwardt F (1989). Development of hirudin as an antithrombotic agent. Semin. Thromb. Hemost. 15(3): 269-282.
10. Markwardt F (1994). The development of hirudin as an antithrombotic drug. Thromb. Res. 74(1):1-23.
11. Niu JY, Dong CN, Jin JD, Shi BX, Wu ZZ (2006). Design and functional investi- gation of a novel anti-coagulative fusion protein by hirudin with a recognizing sequence of FXa. Zhongguo Sheng Wu Gong Cheng Za Zhi. 26: 36-39.
12. Rosenfeld SA, Nadeau D, Tirado J, Hollis GF, Knabb RM, Jia S (1996). Production and purification of recombinant hirudin expressed in the methylotrophic yeast Pichia pastoris. Protein Expr. Purif. 8(4): 476-482.
13. Seemmuller U, Dodt J, Fink E, Fritz H (1986). Proteinase inhibitors of the leech Hirudo medicinialis (hirudins, bdellins, eglins). In: Barrett AJ, Salvesen G (eds). Proteases. Elsevier, Amsterdam, pp. 337-359.
14. Smith JW, Tachias K, Madison EL (1995). Protein loop grafting to construct a variant of tissue-type plasminogen activator that binds platelet integrin alpha IIb beta 3. J. Biol. Chem. 270(51): 30486-30490.
15. Zhang YG, Yue L, Wang YX, Tao XM, Song HY (2006). Design of a novel plasminogen activator based on the structure of hirudin. Acta Biochim. Biophys. Sin. (Shanghai). 38(8): 531-536.
16. Zhou X, Huang Y X, Zhu S G (2001). Construction and expression of chimeric antithrombotics with hirudin and RGD Sequence. Beijing Da Xue Xue Bao Zi Ran Ke Xue Bao. 37: 490-495.
17. Zokai K, Piazolo L, Harenberg J (2001). Effect of thrombin inhibitors and a glycoprotein IIb/IIIa receptor antagonist in an ex vivo human experimental thrombosis model. Semin. Thromb. Hemost. 27(5): 531-536.